Could a blood trait change how we dose chemo?
NCT ID NCT07341867
First seen Jun 24, 2026 · Last updated Jul 17, 2026 · Updated 2 times
Summary
This study tests whether adjusting cancer drug doses for people with the Duffy null blood trait can reduce treatment delays and dangerous fevers. About 90 participants with multiple myeloma or triple-negative breast cancer will receive standard chemotherapy with modified dosing guidelines. The goal is to see if these adjustments help avoid dose reductions and lower the risk of neutropenic fever.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Dexamethasone, Bortezomib, Lenalidomide, Daratumumab, Carboplatin, Paclitaxel, Pembrolizumab, Cyclophosphamide, Doxorubicin
- What this could lead to
- If successful, this could lead to safer and more effective cancer treatment dosing for people with the Duffy null blood trait, reducing complications like fever and treatment delays.
- What could go wrong
- This is a small early-phase pilot study, so results may not apply broadly. The dose adjustments are new and untested, and there is no guarantee they will improve outcomes or safety.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DUFFY BLOOD GROUP, CHEMOKINE RECEPTOR GENE C.-67T>C are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Dana-Farber Cancer Institute
Boston, Massachusetts, 02215, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could muscle loss predict blood cancer outcomes?
- Can a Triple-Action antibody deepen remissions in myeloma?
- Can a Low-Dose antifungal shield vulnerable patients from deadly fungal infections?
- Can a gentler chemo prep make stem cell transplants safer for blood cancer patients?
- Can a High-Fiber diet shield the gut during breast cancer therapy?
- Talking about the end: could guided conversations reduce futile cancer treatments?